These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 6818587)

  • 41. [Studies on the long acting neuroleptic agent flupenthixol decanoate--a review (author's transl)].
    Sieberns S
    Pharmakopsychiatr Neuropsychopharmakol; 1978 Jul; 11(4):186-98. PubMed ID: 674354
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Persistence of fluphenazine in plasma after decanoate withdrawal.
    Gitlin MJ; Midha KK; Fogelson D; Nuechterlein K
    J Clin Psychopharmacol; 1988 Feb; 8(1):53-6. PubMed ID: 3351000
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Radioreceptor assay in checking serum concentration in long-term treatment with cis(z)-flupenthixol decanoate.
    Lipska B; Welbel L; Nurowska K; Szukalski B
    Act Nerv Super (Praha); 1987 Dec; 29(4):270-3. PubMed ID: 3439426
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Double-blind placebo substitution: withdrawal of fluphenazine decanoate in schizophrenic patients.
    Odejide OA; Aderounmu AF
    J Clin Psychiatry; 1982 May; 43(5):195-6. PubMed ID: 7076630
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Further observations on the duration of depot neuroleptic maintenance therapy in schizophrenia.
    Johnson DA
    Br J Psychiatry; 1979 Dec; 135():524-30. PubMed ID: 534806
    [No Abstract]   [Full Text] [Related]  

  • 46. Disturbances of liver function of long acting neuroleptic drugs.
    Nolen WA; Börger J
    Pharmakopsychiatr Neuropsychopharmakol; 1978 Jul; 11(4):199-204. PubMed ID: 674355
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Letter: Choreiform movements after depot injections of flupenthixol.
    Carney MW
    Br J Psychiatry; 1974 Dec; 125():609. PubMed ID: 4457212
    [No Abstract]   [Full Text] [Related]  

  • 48. Peroral and parenteral administration of long-acting neuroleptics: a double-blind study of penfluridol compared to flupenthixol decanoate in the treatment of schizophrenia.
    Gerlach J; Kramp P; Kristjansen P; Lauritsen B; Lühdorf K; Munkvad I
    Acta Psychiatr Scand; 1975 Aug; 52(2):132-44. PubMed ID: 1096541
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Double-blind comparison of haloperidol decanoate and fluphenazine decanoate effectiveness, side-effects, dosage and serum levels during a six months' treatment for relapse prevention.
    Kissling W; Möller HJ; Walter K; Wittmann B; Krueger R; Trenk D
    Pharmacopsychiatry; 1985 May; 18(3):240-5. PubMed ID: 4011672
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Plasma levels of fluphenazine in patients receiving fluphenazine decanoate. Relationship to clinical response.
    Marder SR; Midha KK; Van Putten T; Aravagiri M; Hawes EM; Hubbard JW; McKay G; Mintz J
    Br J Psychiatry; 1991 May; 158():658-65. PubMed ID: 1860020
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Plasma fluphenazine levels by radioimmunoassay in schizophrenic patients treated with depot injections of fluphenazine decanoate.
    Wiles DH; Gelder MG
    Adv Biochem Psychopharmacol; 1980; 24():599-602. PubMed ID: 7405678
    [No Abstract]   [Full Text] [Related]  

  • 52. [Comparative study of the effects of fluphenazine-depot and flupenthixol-depot in the treatment of schizophrenic psychoses].
    Bilikiewicz A; Sep-Kowalikowa B
    Psychiatr Pol; 1976; 10(4):359-66. PubMed ID: 981411
    [No Abstract]   [Full Text] [Related]  

  • 53. Radioimmunoassay for flupenthixol in plasma.
    Robinson JD; Risby D
    Clin Chem; 1977 Nov; 23(11):2085-8. PubMed ID: 912874
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Haloperidol decanoate and flupenthixol decanoate in schizophrenia. A long-term double-blind cross-over comparison.
    Eberhard G; Hellbom E
    Acta Psychiatr Scand; 1986 Sep; 74(3):255-62. PubMed ID: 3788652
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Pharmacokinetic studies on flupenthixol decanoate, a depot neuroleptic of the thioxanthene group.
    Jørgensen A
    Drug Metab Rev; 1978; 8(2):235-49. PubMed ID: 720214
    [No Abstract]   [Full Text] [Related]  

  • 56. Depot injections for affective disorders.
    Naylor GJ; Scott CR
    Br J Psychiatry; 1980 Jan; 136():105. PubMed ID: 7357213
    [No Abstract]   [Full Text] [Related]  

  • 57. The discontinuance of maintenance neuroleptic therapy in chronic schizophrenic patients: drug and social consequences.
    Johnson DA; Pasterski G; Ludlow JM; Street K; Taylor RD
    Acta Psychiatr Scand; 1983 May; 67(5):339-52. PubMed ID: 6135298
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Dose and serum drug level and its clinical effects during the long-term treatment of chronic schizophrenia with flupenthixol depot].
    Lipska B; Szukalski B; Nurowska K; Welbel L
    Psychiatr Pol; 1986; 20(1):1-7. PubMed ID: 3725983
    [No Abstract]   [Full Text] [Related]  

  • 59. Impact of clinical pharmacokinetics on neuroleptic therapy in patients with schizophrenia.
    Midha KK; Hubbard JW; Marder SR; Marshall BD; Van Putten T
    J Psychiatry Neurosci; 1994 Jul; 19(4):254-64. PubMed ID: 7918346
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Relapse in chronic schizophrenics treated with fluphenazine decanoate is associated with low serum neuroleptic levels.
    Jayaram G; Coyle J; Tune L
    J Clin Psychiatry; 1986 May; 47(5):247-8. PubMed ID: 3700342
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.